Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

June 20, 2025

Study Completion Date

July 4, 2025

Conditions

Gynecological Tumor

Interventions

DRUG

Aprepitant Injection

Two antiemetic groups use placebo,Dexamethasone and Ondansetron, Three antiemetic groups use Aprepitant,Dexamethasone and Ondansetron.

Trial Locations (2)

Dengfeng Wang, Chengdu

Sichuan Cancer Hospital, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT06007586 - Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | Biotech Hunter | Biotech Hunter